Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05426174 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older
A Phase 1 study, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 233
- Enrollment target
NCT05426174 is a Phase 1 study that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 233 participants.
The verdict
NCT05426174, a Phase 1 study, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 233 participants
- Enrollment target
Study Summary
This is a Phase I, first-in-human, randomized, modified double-blind, active-controlled, dose-escalation study to assess the safety and immunogenicity of up to 3 dose levels of mRNA NA vaccines, administered as a single IM injection in healthy adults aged 18 years and older. Two age groups, 18 to 64 years and ≥65 years, will be included in this study.
Interventions
- BIOLOGICAL mRNA NA vaccine
- BIOLOGICAL High Dose Quadrivalent Influenza Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 233 participants |
| Start Date | 2022-06-09 |
| Est. Completion | 2024-01-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05426174
The ClinicalTrials.gov registry entry for NCT05426174 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 233 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which mRNA NA vaccine is the first listed.
NCT05426174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05426174 about?
NCT05426174 is a clinical study titled "Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older". This is a Phase I, first-in-human, randomized, modified double-blind, active-controlled, dose-escalation study to assess the safety and immunogenicity of up to 3 dose levels of mRNA NA vaccines, administered as a single IM injection in healthy adults aged 18 years and older. Two age groups, 18 to 64...
What is the current status of trial NCT05426174?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 233 participants. The study started on 2022-06-09. Estimated completion is 2024-01-03.
What interventions are being tested in trial NCT05426174?
The interventions under investigation include: mRNA NA vaccine (BIOLOGICAL), High Dose Quadrivalent Influenza Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05426174?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.